{"id":"can-2409","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to CD3 on T-cells and recruiting them to the tumor microenvironment, where they can recognize and kill cancer cells. This approach allows for a targeted and sustained activation of T-cells, potentially leading to improved anti-tumor responses.","oneSentence":"CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:19.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic solid tumors"}]},"trialDetails":[{"nctId":"NCT07332000","phase":"PHASE2","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","status":"RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2025-10-30","conditions":"Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)","enrollment":45},{"nctId":"NCT04495153","phase":"PHASE2","title":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2020-10-13","conditions":"Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT02768363","phase":"PHASE2","title":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2016-05","conditions":"Prostate Cancer","enrollment":187},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT03131037","phase":"PHASE1","title":"Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2017-05-04","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT00589875","phase":"PHASE2","title":"Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2007-03","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":52},{"nctId":"NCT02446093","phase":"PHASE2","title":"Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2015-10","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAN-2409","genericName":"CAN-2409","companyName":"Candel Therapeutics, Inc.","companyId":"candel-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor. Used for Metastatic solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}